PMCB - PharmaCyte Biotech, Inc.
IEX Last Trade
1.565
0 0%
Share volume: 21
Last Updated: Fri 27 Dec 2024 08:09:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.56
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.50%
1 Month
-8.77%
3 Months
-15.22%
6 Months
-25.00%
1 Year
-29.73%
2 Year
-46.39%
Key data
Stock price
$1.56
DAY RANGE
$1.56 - $1.56
52 WEEK RANGE
$1.55 - $2.58
52 WEEK CHANGE
-$27.78
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Joshua N. Silverman
Region: US
Website: pharmacyte.com
Employees: 4
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pharmacyte.com
Employees: 4
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
PharmaCyte Biotech, Inc. focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer.
Recent news